as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹6,459.0
Change
-31.5 (-0.49%)
Open
₹6,483.5
Prev. Close
₹6,490.5
Day High
₹6,552.5
Day Low
₹6,424.5
Volume Analysis
Traded
3,125
Delivered
1,852
Delivery %
59.26%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (22.2%)
- •Strong operating margin (22.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹6,660.84 | ₹6,606.67 | ₹6,532.84 | ₹6,478.67 | ₹6,404.84 | ₹6,350.67 | ₹6,276.84 |
| Fibonacci | ₹6,606.67 | ₹6,557.77 | ₹6,527.57 | ₹6,478.67 | ₹6,429.77 | ₹6,399.57 | ₹6,350.67 |
| Camarilla | ₹6,494.2 | ₹6,482.47 | ₹6,470.73 | ₹6,478.67 | ₹6,447.27 | ₹6,435.53 | ₹6,423.8 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-1.08%
1 Month
+11.71%
3 Months
+7.03%
6 Months
+19.76%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹561.04
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
20.17%
Net margin 9.8% × asset turnover 0.98x × equity multiplier 2.1x
Company Overview
Sector
Healthcare
Market Cap
₹7,108 Cr
P/E (TTM)
123.0
ROE
22.2%
Book Value
₹264.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Kovai Medical Center & Ho lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Momentum (85/100), while Valuation (1/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (22.2%); strong operating margin (22.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
64/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has a good return on equity (ROE) track record: 3 Years ROE 25.5%
- +Company's median sales growth is 19.0% of last 10 years
- −Stock is trading at 24.6 times its book value
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
We enclose the copies of Newspaper Advertisement published in English and Tamil on 12th November, 2026 with regard to Un-Audited Financial Results for the quarter …
Board extended AHS division slump sale deadline to 31 Jan 2027 and lease till 30 Apr 2027.
Board approved Q2 FY27 results; customs order demands ₹2.11 crore plus about ₹10 crore interest.
Customs adjudication order demands Rs.1.89 crore duty, Rs.3 lakh fine and Rs.18.95 lakh penalty on 28 Oct 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 303 | 321 | 321 | 315 | 344 | 355 | 357 | 374 | 392 | 407 | 414 | 431 | 473 |
| Expenses + | 217 | 225 | 229 | 229 | 248 | 252 | 256 | 268 | 285 | 291 | 303 | 307 | 336 |
| Operating Profit | 85 | 96 | 92 | 86 | 96 | 103 | 101 | 106 | 107 | 116 | 111 | 124 | 137 |
| OPM % | 28.0% | 30.0% | 29.0% | 27.0% | 28.0% | 29.0% | 28.0% | 28.0% | 27.0% | 28.0% | 27.0% | 29.0% | 29.0% |
| Other Income + | 4 | 5 | 6 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 8 | 7 | 8 |
| Interest | 8 | 7 | 7 | 7 | 8 | 9 | 9 | 9 | 9 | 8 | 6 | 8 | 8 |
| Depreciation | 23 | 23 | 24 | 24 | 24 | 25 | 25 | 26 | 27 | 28 | 29 | 32 | 33 |
| Profit before tax | 58 | 71 | 67 | 61 | 67 | 75 | 74 | 76 | 78 | 87 | 84 | 92 | 104 |
| Tax % | 26.0% | 25.0% | 22.0% | 25.0% | 25.0% | 23.0% | 26.0% | 25.0% | 24.0% | 25.0% | 25.0% | 25.0% | 26.0% |
| Net Profit + | 43 | 53 | 52 | 46 | 51 | 58 | 55 | 57 | 59 | 65 | 63 | 69 | 77 |
| EPS in Rs | 40 | 49 | 48 | 42 | 46 | 53 | 50 | 52 | 54 | 59 | 58 | 63 | 70 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 20 | 21 | 20 | 15 | 14 | 11 | 11 | 19 | 14 | 15 | 16 | 15 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 88 | 110 | 130 | 175 | 222 | 297 | 334 | 402 | 465 | 531 | 592 |
| Expenses + | 73 | 91 | 104 | 138 | 178 | 226 | 261 | 307 | 373 | 406 | 463 |
| Operating Profit | 15 | 19 | 26 | 37 | 44 | 71 | 73 | 95 | 92 | 125 | 129 |
| OPM % | 17.0% | 17.0% | 20.0% | 21.0% | 20.0% | 24.0% | 22.0% | 24.0% | 20.0% | 24.0% | 22.0% |
| Other Income + | 1 | 1 | 2 | 1 | 1 | 3 | 5 | 7 | 8 | 6 | 8 |
| Interest | 3 | 4 | 5 | 11 | 17 | 27 | 24 | 20 | 17 | 15 | 13 |
| Depreciation | 5 | 4 | 5 | 7 | 13 | 16 | 16 | 22 | 21 | 24 | 34 |
| Profit before tax | 7 | 11 | 17 | 20 | 16 | 31 | 37 | 59 | 62 | 92 | 89 |
| Tax % | 41.0% | 35.0% | 33.0% | 38.0% | 26.0% | 33.0% | 36.0% | 35.0% | 35.0% | 35.0% | 35.0% |
| Net Profit + | 4 | 7 | 12 | 12 | 12 | 20 | 24 | 39 | 41 | 60 | 58 |
| EPS in Rs | 4 | 7 | 11 | 11 | 11 | 19 | 22 | 35 | 37 | 55 | 53 |
| Dividend Payout % | 32.0% | 19.0% | 12.0% | 11.0% | 11.0% | 8.0% | 7.0% | 4.0% | 7.0% | 5.0% | 6.0% |
| Sales growth | — | 26 | 18 | 34 | 27 | 34 | 12 | 20 | 16 | 14 | 12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 13 | 19 | 29 | 40 | 50 | 68 | 90 | 126 | 163 | 223 | 278 |
| Borrowings + | 38 | 70 | 108 | 192 | 228 | 209 | 184 | 163 | 158 | 125 | 202 |
| Other Liabilities + | 31 | 25 | 25 | 41 | 50 | 55 | 65 | 85 | 96 | 103 | 116 |
| Total Liabilities | 93 | 126 | 173 | 283 | 338 | 344 | 350 | 384 | 428 | 462 | 606 |
| Fixed Assets + | 62 | 69 | 106 | 193 | 295 | 285 | 282 | 285 | 342 | 358 | 444 |
| CWIP | 6 | 20 | 42 | 38 | 0 | 5 | 5 | 17 | 10 | 6 | 13 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 25 | 36 | 25 | 53 | 43 | 54 | 62 | 83 | 76 | 99 | 149 |
| Total Assets | 93 | 126 | 173 | 283 | 338 | 344 | 350 | 384 | 428 | 462 | 606 |
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | — | 15 | 24 | 42 | 56 | 61 | 68 | 97 | 86 | 99 | 87 |
| Cash from Investing Activity + | — | -23 | -64 | -97 | -77 | -9 | -12 | -80 | -115 | -83 | -191 |
| Cash from Financing Activity + | — | 27 | 31 | 71 | 17 | -48 | -52 | -43 | -24 | -50 | 60 |
| Net Cash Flow | — | 18 | -9 | 16 | -3 | 5 | 4 | -26 | -53 | -34 | -45 |
| Free Cash Flow | — | -8 | -41 | -56 | -21 | 51 | 53 | 60 | 15 | 63 | -41 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | — | 97 | 113 | 123 | 136 | 96 | 103 | 119 | 110 | 100 | 92 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 39.24% | 39.02% | 38.91% | 38.67% | 38.46% | 38.32% | 37.65% | 37.34% | 37.43% | 37.8% | 37.98% | 37.94% |
| Promoters | 56.44% | 56.47% | 56.5% | 56.51% | 56.55% | 56.55% | 56.55% | 56.52% | 56.53% | 56.53% | 56.53% | 56.54% |
| FII | 2.24% | 0.34% | 0.32% | 0.44% | 0.55% | 1.1% | 1.27% | 1.25% | 1.31% | 1.21% | 1.25% | 1.22% |
| DII | 2.09% | 4.18% | 4.28% | 4.37% | 4.43% | 4.03% | 4.52% | 4.89% | 4.73% | 4.47% | 4.24% | 4.31% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Kovai Medical Center & Ho (this stock) | 7,108 | 123.0 | 24.58 | 22.2% |
| Bliss Gvs Pharma Ltd | 7,075 | 43.5 | 5.5 | 11.8% |
| Sanofi India Limited | 7,375 | 16.7 | 8.56 | 47.1% |
| Sun Pharma Adv.res.co.ltd | 6,680 | 4.05 | 4.64 | 279.0% |
| Nephrocare Health Serv L | 6,500 | 50.8 | 5.46 | 8.83% |
| Suven Life Sciences Ltd | 7,850 | — | 17.38 | -81.5% |
| Thyrocare Tech Ltd | 7,940 | 45.3 | 14.31 | 28.4% |
Which Mutual Funds Hold Kovai Medical Center & Ho?
Frequently Asked Questions about Kovai Medical Center & Ho
Kovai Medical Center & Ho (KOVAI) closed at ₹6,459.0 on NSE on 19 November 2026, down 31.5 (0.49%) from the previous close.
Kovai Medical Center & Ho trades on the NSE (National Stock Exchange of India) under the symbol KOVAI.
Kovai Medical Center & Ho has a trailing twelve-month P/E (price-to-earnings) ratio of 123.0.
Kovai Medical Center & Ho has a dividend yield of 0.23%.
Kovai Medical Center & Ho's 52-week high is ₹6,750.0 and its 52-week low is ₹5,010.0.
Kovai Medical Center & Ho has a market capitalisation of ₹7,108 crore.
Kovai Medical Center & Ho has a TopFund Quality Score of 64/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Kovai Medical Center & Ho?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.